Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by tylerreddickon Oct 04, 2024 12:21pm
147 Views
Post# 36253445

Financing coming soon

Financing coming soonThis comment from Hopton makes me think they are in the final stages of getting the financing;

While dilution concerns remain, we are confident that our plans will generate significant shareholder value, offsetting these concerns. "

They never previously admitted that the financing would be dilutive, so I am thinking they are preparing us for that.

But the bottom line is that we need money to get GPM to market, and no one is going to give us that money without sharing in the potential benefits. So I am fine with whatever the terms are, as our share will still be worth far more than 8 stinkin cents, that is for sure.

And if Abbvie eventually comes through, after they see they can't bankrupt us, that is just a bonus.
<< Previous
Bullboard Posts
Next >>